36,140 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Carret Asset Management LLC

Carret Asset Management LLC bought a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 36,140 shares of the company's stock, valued at approximately $271,000. Carret Asset Management LLC owned about 0.07% of Zevra Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in Zevra Therapeutics during the fourth quarter valued at approximately $53,000. GAMMA Investing LLC increased its stake in shares of Zevra Therapeutics by 20,564.1% in the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after purchasing an additional 8,020 shares in the last quarter. Squarepoint Ops LLC raised its holdings in Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock worth $138,000 after purchasing an additional 4,384 shares during the period. ProShare Advisors LLC purchased a new position in Zevra Therapeutics during the fourth quarter valued at $145,000. Finally, Invesco Ltd. grew its holdings in Zevra Therapeutics by 19.6% during the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after purchasing an additional 3,007 shares during the period. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Price Performance

ZVRA traded up $0.15 during trading hours on Tuesday, hitting $9.15. The company's stock had a trading volume of 316,726 shares, compared to its average volume of 670,205. The stock has a market cap of $500.32 million, a price-to-earnings ratio of -4.82 and a beta of 2.01. The business's 50-day moving average price is $8.24 and its 200-day moving average price is $8.05. The company has a current ratio of 3.02, a quick ratio of 2.93 and a debt-to-equity ratio of 1.46. Zevra Therapeutics, Inc. has a 12 month low of $4.20 and a 12 month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. The company had revenue of $20.40 million during the quarter, compared to analyst estimates of $16.96 million. During the same quarter last year, the business posted ($0.40) earnings per share. Sell-side analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ZVRA shares. Guggenheim raised their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Canaccord Genuity Group boosted their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $22.29.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.